Dr. Perlmutter's NeuroActives BrainSustain Tier 3

NeuroActives BrainSustain Tier 3™ provides the same potent neuroactive ingredients found in our powder formulas but in a convenient capsule form!

120 capsules

Directions: Take 4-8 capsules daily or as directed by your healthcare practitioner.

Other Ingredients: Hypromellose (derived from cellulose and contains no animal byproducts) capsule, magnesium citrate, leucine, silicon dioxide. Contains an ingredient derived from soy.

WARNING: Keep out of reach of children. Consult your healthcare practitioner before taking this product.
TAMPER EVIDENT: Use only if bottle is sealed. Store tightly sealed in a cool dry place.

More information on the potent ingredients in Dr. Perlmutter's NeuroActives BrainSustain

• Coenzyme Q-10 measurably increases the efficiency of cellular energy production, as demonstrated in studies performed at the Massachusetts General Hospital.¹ In addition, it serves as a potent brain antioxidant. These effects explain why major institutions worldwide are vigorously evaluating coenzyme Q10 as a therapeutic aid in brain disorders.
• Alpha Lipoic Acid provides powerful antioxidant action and regenerates other important brain antioxidants including vitamins E, C, and glutathione. Unlike other antioxidants, alpha lipoic acid is both fat- and water-soluble, greatly enhancing its ability to be absorbed from the gut and penetrate into the brain.²
• N-Acetyl-L-Cysteine (NAC) dramatically increases the body's production of glutathione, one of the brain's most important antioxidants. NAC itself is a potent antioxidant shown to reduce formation of nitric oxide, a free radical implicated for a causative role in Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders.³
• Acetyl-L-Carnitine, like coenzyme Q-10, enhances neuronal energy production by transporting fuel sources into the mitochondria — the energy producing machinery of the neuron. This particularly benefits damaged brain neurons, which are characterized by decreased energy production. In addition, acetyl-L-carnitine acts as an effective antioxidant and been demonstrated to protect laboratory animals from developing parkinsonism when they are exposed to chemicals known to induce the condition.⁴ A report in a recent issue of Neurology found that acetyl-L-carnitine profoundly reduces the rate of progression of Alzheimer's disease in younger patients.⁵
• Gingko biloba, one of the most extensively studied nutritional supplements for neurodegenerative conditions, directly improves brain metabolism, increases brain blood flow, and provides antioxidant action. In a placebo-controlled, double-blind randomized trial published in the Journal of the American Medical Association, Gingko biloba not only stabilized Alzheimer's disease, but in addition, many subjects demonstrated an actual improvement noted in various standardized psychological tests.⁶
• Phosphatidylserine produces marked memory and learning improvements in demented patients, according to research conducted at Stanford University.⁷ Like acetyl-L-carnitine and coenzyme Q-10, phosphatidylserine plays an important role in neuronal energy production and chemical communication.

References

1. Schults, C.W., Beal, M.F., Fontaine, K., et al. Absorption, tolerability and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonsian patients, Neurology 50: 793-795, 1998. [ Back ^ ]
2. Marangon, K., Deveraj, S., Tirosh, O., et al., Comparison of the effect of a-lipoic acid and a-tocopherol supplementation on measures of oxidative stress. Free Radical Biology and Medicine 27(9/10): 1114-1121, 1999. [ Back ^ ]
3. Pahan, K., Sheikh, G.S., Nmboodri, A.M.S., et al., N-acetyl cysteine inhibits induction of NO production by endotoxin or cytokine stimulated rat peri-toneal macrophages, C6 glial cells and astrocytes. Free Radical Biology and Medicine 24(1):39-48, 1998. [ Back ^ ]
4. Steffen V. Santiago, M., de la Cruz, C.P., et al., Effect of intraventricular injection of 1-methyl-4-phenylpridinium protection by acetyl-L-carnitine. Human Exp Toxicol 14:865-871, 1995. [ Back ^ ]
5. Thal L.J., Carta A. Clarke, W.R., et al., A 1-year multicenter placebo-con-trolled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 47:705-711, 1996. [ Back ^ ]
6. Le Bars, P., Katz, M.M., Berman, N., et al,. a Placebo-Controlled, Double-blind Randomized Trial of an Extract of Gingko Biloba for Dementia. JAMA 278(16): 1327-32, 1997. [ Back ^ ]
7. Crook, T.H., Tinklenberg, J., Yesavage, J., Effects of phosphatidylserine in age-associated memory impairment. Neurology 41:644-49, 1991. [ Back ^ ]